These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31899530)

  • 21. Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression.
    Xu Y; Wei H; Zhu Y; Zhu Y; Zhang N; Qin J; Zhu X; Yu M; Li Y
    J Affect Disord; 2019 May; 250():307-312. PubMed ID: 30875673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of escitalopram and severity of depression: new data].
    Spadone C
    Encephale; 2009 Dec; 35(6):577-85. PubMed ID: 20004289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
    Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
    J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting tDCS treatment outcomes of patients with major depressive disorder using automated EEG classification.
    Al-Kaysi AM; Al-Ani A; Loo CK; Powell TY; Martin DM; Breakspear M; Boonstra TW
    J Affect Disord; 2017 Jan; 208():597-603. PubMed ID: 28029427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
    Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
    BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study.
    Arns M; Gordon E; Boutros NN
    Clin EEG Neurosci; 2017 Jan; 48(1):33-40. PubMed ID: 26674366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
    Montgomery SA; Möller HJ
    Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Debunking the placebo effect in depression: the effect of patient and investigator expectation on escitalopram efficacy.
    Nehama Y; Rabinowitz I; Baruch Y; Mandel A; Lurie I; Barak Y
    Int Clin Psychopharmacol; 2014 Mar; 29(2):106-10. PubMed ID: 24172161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
    Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
    Kasper S; Ebert B; Larsen K; Tonnoir B
    Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
    Lepola U; Wade A; Andersen HF
    Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L; Tonnoir B; Arbus C
    Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram continuation treatment prevents relapse of depressive episodes.
    Rapaport MH; Bose A; Zheng H
    J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.